摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

cycotiamine | 59366-41-5

中文名称
——
中文别名
——
英文名称
cycotiamine
英文别名
N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[(1Z)-1-(2-oxo-1,3-oxathian-4-ylidene)ethyl]formamide
cycotiamine化学式
CAS
59366-41-5
化学式
C13H16N4O3S
mdl
——
分子量
308.361
InChiKey
LLJDJQYGZBQFIF-FLIBITNWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    124
  • 氢给体数:
    1
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    三光气盐酸硫胺 在 sodium hydroxide 作用下, 以 为溶剂, 以0.12 g的产率得到cycotiamine
    参考文献:
    名称:
    含硫类化合物、其药物组合物及应用
    摘要:
    本发明公开了一种含硫类化合物、其药物组合物及应用。本发明提供了一种物质A在制备Aβ40和/或Aβ42蛋白抑制剂或药物中的应用;所述的药物为用于治疗和/或由Aβ40和/或Aβ42蛋白介导的疾病的药物或者用于治疗和/或预防神经退行性疾病或衰老的药物,所述的物质A选自如式A1等所示的化合物或其药学上可接受的盐。本发明的化合物,对Aβ40及Aβ42蛋白具有良好的抑制作用,有望治疗和/或预防神经退行性疾病或衰老药物。#imgabs0#
    公开号:
    CN117417301A
点击查看最新优质反应信息

文献信息

  • [EN] POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS POLYMÉRIQUES HYPERBRANCHÉS
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013024048A1
    公开(公告)日:2013-02-21
    The present invention relates to water-soluble carrier-linked prodrugs of formula (I),wherein POL is a polymeric moiety,each Hyp is independently a hyperbranched moiety,each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water- soluble carrier-linked prodrugs and methods of treatment.
    本发明涉及水溶性载体连接的前药,其化学式为(I),其中POL是聚合物基团,每个Hyp是独立的超支化基团,每个基团SP是独立的间隔基团,每个L是独立的可逆前药连接基团,m为0或1,每个n是独立的整数,范围从2到200,每个x是独立的0或1。此外,还涉及包含所述水溶性载体连接的前药的药物组合物和治疗方法。
  • [EN] HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS HYDROSOLUBLES DE FORTE CHARGE
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013024047A1
    公开(公告)日:2013-02-21
    The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independendly a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use asmedicament or diagnostic, and methods of treatment.
    本发明涉及水溶性载体连接的前药,其化学式为(I),其中B、A和Hyp形成载体,B是一个分支核心,每个A独立地是一条聚乙二醇基聚合链,每个Hyp独立地是一个分支基团,每个SP独立地是一个间隔基团,每个L独立地是一个可逆前药连接基团,每个D独立地是一个生物活性基团,每个x独立地为0或1,每个m独立地是从2到64的整数,n是从3到32的整数;或其药学上可接受的盐。进一步涉及包括所述水溶性载体连接的前药的药物组合物,其用作药物或诊断,以及治疗方法。
  • [EN] PROTEIN CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À UN EXCIPIENT PROTÉIQUE
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013024049A1
    公开(公告)日:2013-02-21
    The present invention relates to water-soluble protein carrier- linked prodrugs wherein the protein carrier comprises an amino acid sequence consisting of at least 100 amino acid residues forming random coil conformation and comprising alanine, serine and proline residues. It further relates to pharmaceutical compositions comprising said water-soluble protein carrier- linked prodrugs, their use as a medicament as well as methods of treatment and administration.
    本发明涉及水溶性蛋白载体连接的前药,其中蛋白载体包括至少100个氨基酸残基组成的氨基酸序列,形成随机卷曲构象,包括丙氨酸、丝氨酸和脯氨酸残基。还涉及包含上述水溶性蛋白载体连接的前药的药物组合物,它们作为药物的用途,以及治疗和管理的方法。
  • [EN] HYDROGEL-LINKED PRODRUGS RELEASING MODIFIED DRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À UN HYDROGEL LIBÉRANT DES MÉDICAMENTS MODIFIÉS
    申请人:ASCENDIS PHARMA AS
    公开号:WO2014173759A1
    公开(公告)日:2014-10-30
    The present invention relates to a process for the preparation of a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate, to a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate obtainable by such process, to pharmaceutical compositions comprising said prodrug and their use as a medicament.
    本发明涉及一种制备水凝胶连接的前药释放标签基团-生物活性基团结合物的方法,以及通过该方法获得的水凝胶连接的前药释放标签基团-生物活性基团结合物,还涉及包含该前药的药物组合物及其作为药物的用途。
  • ANTI-INFLAMMATORY PEPTIDE
    申请人:Sato Kenji
    公开号:US20110183925A1
    公开(公告)日:2011-07-28
    Provided is an anti-inflammatory composition which has a high efficacy, causes no concern about side effects, is easy to ingest, and can also be administered for a long period of time because of its low cost and high safety. The present invention relates to a peptide comprising an amino acid sequence represented by pyroGlu-(X)n-A or a salt thereof, wherein X is independently Gln, Asn, or Pro; A represents Gln, Asn, Leu, Ile, Met, Val, or Phe; and n represents an integer of 0 to 2, and an anti-inflammatory composition comprising the same.
    提供了一种具有高效性、不会引起副作用、易于摄入并且由于成本低和安全性高可以长期使用的抗炎组合物。本发明涉及一种肽,其包含由pyroGlu-(X)n-A或其盐表示的氨基酸序列,其中X独立地表示Gln、Asn或Pro;A表示Gln、Asn、Leu、Ile、Met、Val或Phe;n表示0到2的整数,以及包含其的抗炎组合物。
查看更多